24/7 BIOPHARMA - issue 1 / October 2024

NEWS

Cambrex announces new liquid-phase peptide synthesis manufacturing technology

Cambrex, a leading global contract development and manufacturing

peptide synthesis processes. “Over the past several years, we have made significant investments in the research and development of complex synthetics, specifically

scaled in the same way as traditional small molecules.

organization (CDMO), today announced that Snapdragon

In addition to the LPPS, Cambrex developed unique capabilities in peptide and protein crystallization, including a crystallization screening platform specifically for the discovery of crystalline forms of peptides and proteins. Crystallization can deliver improved product quality and stability and reduce the need for time-consuming preparative chromatography and lyophilization. “With the clinical and commercial successes of peptide-based therapies, it’s imperative that we provide industry-leading solutions to develop and scale peptide candidates,” said Thomas Loewald, CEO at Cambrex. Cambrex will continue to invest in R&D across complex synthetic modalities, including further technology development for peptides, as well as new research on the application of artificial intelligence for the optimization of oligonucleotide processes.

Chemistry, a Cambrex company, has successfully developed a new liquid phase peptide synthesis (LPPS) technology that utilizes traditional active pharmaceutical ingredient (API) batch reactors and continuous flow, obviating the dependency on specialized, solid-phase reactors. This new LPPS technology materially reduces solvent demand and the need for excess reagents compared to standard solid-state

to reduce the economic and environmental impacts of manufacturing peptides and

oligonucleotides,” said Dr. Matt Bio, Chief Scientific Officer, Cambrex. “Our new LPPS technology provides a significantly more cost-efficient and environmentally sustainable solution when compared to traditional solid-phase peptide synthesis, substantially reducing solvent usage and allowing the substitution of sustainable solvents.”

The LPPS technology supports peptides up to 12 residues long, while larger peptides are then assembled in liquid phase, using a convergent fragment coupling approach. Processes developed with Cambrex’s LPPS technology can be

Agarose Bead Technologies expands facility to meet rising global demand for novel therapies market

Agarose Bead Technologies (ABT), a leading manufacturer of high quality agarose resins, proudly announces the completion of a major expansion at its facility located in Northern Spain, Burgos. The 1000 sqm addition positions ABT as one of Europe’s largest manufacturers

of agarose resins, strategically advancing its ability to meet the growing global demand for agarose resins in the pharmaceutical and bioprocessing industry.

and has increased its annual capacity to 100,000 liters of resins per year, enabling the firm to deliver larger scale orders. More storage space will be available to accommodate large volumes of products and ensure a robust and reliable supply chain for customers.

The Burgos site now boasts two new state-of-the-art cleanroom facilities

10 TWENTYFOURSEVENBIOPHARMA Issue 1 / October 2024